Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 08, 2016 2:46pm

183 Views

Post# 24746246

RE:RE:RE:RE:RE:RE:RE:Insider trades ..

Hi GV.

Thanks for the digging and posting. My perceptions were wrong because I though both Don and Dr Wong held 7M each but it is 7M combined.

I'm not surprised that other employees held very few shares. I've seen this in ongoing operating companies in which one would expect executives in particular to hold significant amouts of share.

It is encouraging that there lot's of options because that provides a time limited incentive to get the share price moving.

Also great to see that Ken Lebioda, VP business development, is in for 85,000 shares. However, if he unloads at around the $1.25 level then I'll be bailing!!!

Cheers
Toinv

Bullboard Posts

Mullen Group: Navigates market challenges towards success